This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ proscillaridin a,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Congestive Heart Failure (CHF): Proscillaridin A has been used in the past for the treatment of congestive heart failure, a condition in which the heart is unable to pump blood effectively to meet the body's needs. It works by increasing the force of contraction of the heart muscle (positive inotropic effect), which can help improve cardiac output and alleviate symptoms such as shortness of breath and fatigue.

  2. Atrial Fibrillation: Proscillaridin A has also been used to control heart rhythm disturbances such as atrial fibrillation, a common type of irregular heartbeat characterized by rapid and chaotic electrical impulses in the upper chambers of the heart (atria). By slowing down the heart rate and enhancing the regularity of heart rhythm, proscillaridin A may help reduce symptoms associated with atrial fibrillation, such as palpitations and dizziness.

  3. Antiarrhythmic Effects: Proscillaridin A exhibits antiarrhythmic properties by prolonging the refractory period (the time during which the heart muscle cannot be re-stimulated) and suppressing abnormal electrical activity in the heart. This can help prevent the occurrence of certain types of cardiac arrhythmias, including ventricular tachycardia and ventricular fibrillation, which can be life-threatening if left untreated.

  4. Caution and Side Effects: Despite its potential benefits in managing certain cardiac conditions, proscillaridin A carries a significant risk of toxicity and side effects, particularly when used at high doses or in patients with impaired renal function. Common side effects may include nausea, vomiting, diarrhea, headache, visual disturbances, and arrhythmias. Excessive doses of proscillaridin A can lead to severe toxicity, including life-threatening cardiac arrhythmias, electrolyte disturbances (such as hypokalemia and hyperkalemia), and even death.

  5. Narrow Therapeutic Index: Proscillaridin A has a narrow therapeutic index, meaning that there is a small margin between the therapeutic dose and the dose that can cause toxicity. Therefore, careful dosing and close monitoring of patients are essential to minimize the risk of adverse effects.

  6. Drug Interactions: Proscillaridin A can interact with other medications, including diuretics, beta-blockers, calcium channel blockers, and certain antibiotics, potentially enhancing or reducing their effects. Concurrent use of proscillaridin A with other drugs that prolong the QT interval or affect cardiac conduction can increase the risk of arrhythmias.

  7. Contraindications: Proscillaridin A is contraindicated in patients with known hypersensitivity to cardiac glycosides, severe renal impairment, significant electrolyte disturbances (such as hypokalemia and hyperkalemia), and certain types of cardiac arrhythmias (e.g., ventricular fibrillation).

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of proscillaridin a,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by proscillaridin a,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Parabacteroides genus Decreases
0 1 Bilophila genus Decreases
0 1 Lachnospira genus Decreases
0 1 Phocaeicola genus Decreases
0 1 Clostridium genus Decreases
0 1 Thomasclavelia genus Decreases
0 1 Lacticaseibacillus genus Decreases
0 1 Clostridium perfringens A no rank Decreases
0 1 Clostridium perfringens C no rank Decreases
0 1 Clostridium perfringens CPE no rank Decreases
0 1 Clostridium perfringens D no rank Decreases
0 1 Clostridium perfringens B no rank Decreases
0 1 Clostridium perfringens E no rank Decreases
1 0 Lachnospira eligens species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
1 0 Parabacteroides distasonis species Decreases
1 0 Clostridium perfringens species Decreases
1 0 Phocaeicola vulgatus species Decreases
1 0 Bilophila wadsworthia species Decreases
1 0 Thomasclavelia ramosa species Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of proscillaridin a,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.3 0.3
ADHD 0.4 0.4
Age-Related Macular Degeneration and Glaucoma 0.4 -0.4
Allergic Rhinitis (Hay Fever) 0.6 0.6
Allergies 0.6 0.2 2
Allergy to milk products 0.2 0.4 -1
Alopecia (Hair Loss) 0.2 0.2
Alzheimer's disease 0.9 0.5 0.8
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.7 0.7
Ankylosing spondylitis 0.5 0.3 0.67
Anorexia Nervosa 0.6 0.5 0.2
Antiphospholipid syndrome (APS) 0.3 -0.3
Asthma 0.5 0.5
Atherosclerosis 0.3 -0.3
Atrial fibrillation 0.7 0.7 0
Autism 0.8 2.2 -1.75
Autoimmune Disease 0.2 -0.2
Bipolar Disorder 0.9 0.9
Cancer (General) 0.5 -0.5
Carcinoma 0.7 0.4 0.75
Celiac Disease 0.1 1 -9
Cerebral Palsy 0.2 0.2
Chronic Fatigue Syndrome 0.2 0.4 -1
Chronic Kidney Disease 0.4 0.6 -0.5
Chronic Obstructive Pulmonary Disease (COPD) 0.3 -0.3
Chronic Urticaria (Hives) 0.2 0.2
Coagulation / Micro clot triggering bacteria 0.4 0.4
Cognitive Function 0.4 0.2 1
Colorectal Cancer 1 0.5 1
Constipation 0.4 0.4
COVID-19 0.8 0.8 0
Crohn's Disease 1.3 1.4 -0.08
Cushing's Syndrome (hypercortisolism) 0.1 -0.1
Depression 2 1.3 0.54
Eczema 0.2 0.2 0
Endometriosis 0.4 0.3 0.33
Epilepsy 0.1 0.4 -3
erectile dysfunction 0.2 0.2
Fibromyalgia 0.7 0.2 2.5
Functional constipation / chronic idiopathic constipation 1 0.6 0.67
gallstone disease (gsd) 0.6 0.6
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.1 0.3 -2
Generalized anxiety disorder 0.2 -0.2
giant cell arteritis 0.2 -0.2
Gout 0.2 -0.2
Graves' disease 0.4 0.4
Gulf War Syndrome 0.2 0.2
Hashimoto's thyroiditis 0.6 -0.6
Heart Failure 1.3 1.3
hemorrhagic stroke 0.4 0.4
Hidradenitis Suppurativa 0.6 0.6
High Histamine/low DAO 0.3 0.3
hypercholesterolemia (High Cholesterol) 0.2 0.2
hyperglycemia 0.4 -0.4
Hyperlipidemia (High Blood Fats) 0.3 0.3
hypersomnia 0.3 -0.3
hypertension (High Blood Pressure 0.7 0.9 -0.29
Hypoxia 0.7 0.7
IgA nephropathy (IgAN) 0.4 0.9 -1.25
Inflammatory Bowel Disease 0.9 0.8 0.13
Insomnia 0.3 -0.3
Intelligence 0.2 0.2
Intracranial aneurysms 0.4 0.4
Irritable Bowel Syndrome 0.2 1 -4
ischemic stroke 0.4 0.4
Liver Cirrhosis 0.9 0.5 0.8
Long COVID 0.9 1.7 -0.89
Low bone mineral density 0.3 -0.3
Lung Cancer 0.3 0.3
ME/CFS with IBS 0.2 0.2
ME/CFS without IBS 0.2 0.2 0
Metabolic Syndrome 1 1 0
Mood Disorders 1.9 1.3 0.46
Multiple Sclerosis 1.1 1.6 -0.45
myasthenia gravis 0.2 -0.2
neuropathic pain 0.7 -0.7
Neuropathy (all types) 0.4 -0.4
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.5 0.3 0.67
Obesity 1.4 1.3 0.08
obsessive-compulsive disorder 0.8 0.8
Osteoarthritis 0.2 0.2
Osteoporosis 0.2 0.2
Parkinson's Disease 0.9 0.5 0.8
Polycystic ovary syndrome 1 0.5 1
Postural orthostatic tachycardia syndrome 0.2 0.2
Premenstrual dysphoric disorder 0.4 -0.4
primary biliary cholangitis 0.2 -0.2
Primary sclerosing cholangitis 0.6 0.9 -0.5
Psoriasis 0.2 0.7 -2.5
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1 0.2 4
Rosacea 0.2 -0.2
Schizophrenia 1.3 0.9 0.44
scoliosis 0.9 -0.9
Sjögren syndrome 0.4 0.4 0
Sleep Apnea 0.3 0.3
Small Intestinal Bacterial Overgrowth (SIBO) 0.2 0.2
Stress / posttraumatic stress disorder 0.6 0.4 0.5
Systemic Lupus Erythematosus 0.9 0.3 2
Tic Disorder 0.1 0.1
Type 1 Diabetes 0.6 0.6 0
Type 2 Diabetes 1.1 0.8 0.38
Ulcerative colitis 1.2 1 0.2
Unhealthy Ageing 0.4 0.4 0
Vitiligo 0.7 0.6 0.17

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]